Active, not recruitingPHASE1, PHASE2NCT05262023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
Studying Frontotemporal dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Denali Therapeutics Inc.
- Principal Investigator
- Amy Berger, MD, M.DDenali Therapeutics Inc.
- Intervention
- DNL593(drug)
- Enrollment
- 85 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2022 – 2028
Study locations (26)
- University of California San Francisco, San Francisco, California, United States
- John Hopkins University, Baltimore, Maryland, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Antwerp, Antwerp, Belgium
- UZ Leuven, Leuven, Belgium
- L2IP - Instituto de Pesquisas Clinicas LTDA, Brasília, Brazil
- Faculdade de Medicina Da Universidade de São Paulo, São Paulo, Brazil
- Hospital Universitario San Ignacio, Bogotá, Colombia
- Grupo de Neurosicencias de la Universidad de Antioquia, Medellín, Colombia
- Fakultni nemocnice v Motole, Prague, Czechia
- CHU de Nantes, Nantes, France
- CHU Rouen, Rouen, France
- CHU Toulouse, Toulouse, France
- ASST degli Spedali Civili di Brescia, Brescia, Italy
- Azienda Ospedaliera Universitaria Careggi, Florence, Italy
- +11 more locations on ClinicalTrials.gov
Collaborators
Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05262023 on ClinicalTrials.govOther trials for Frontotemporal dementia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07239843Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental DisordersFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- RECRUITINGNCT06856850Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical ApproachesFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT06803784Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative DisordersNeuromed IRCCS
- ENROLLING BY INVITATIONNCT07234851Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ACTIVE NOT RECRUITINGNANCT06768996Music, Social Attention, and DementiaUniversity of California, San Francisco
- RECRUITINGNANCT06668610A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early DementiaUniversity of Campania Luigi Vanvitelli
- RECRUITINGEARLY PHASE1NCT06511752Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive AphasiaUniversity of Texas at Austin
- RECRUITINGNCT06528964Proteinopathies Expression in Skin of Neurodegenerative DisordersUniversidad Autonoma de San Luis Potosí